ストックスクリーナーアプリを入手
1.23
0.00%
0.00
前日終値:
$1.23
開ける：
$1.25
24時間の取引高:
334.41K
Relative Volume:
0.88
時価総額：
$120.01M
収益：
$69.56M
当期純損益:
$-240.05M
株価収益率:
-0.4169
EPS:
-2.95
ネットキャッシュフロー:
$-121.90M
1週間 パフォーマンス:
+1.65%
1か月 パフォーマンス:
-23.60%
6か月 パフォーマンス:
-61.44%
1年 パフォーマンス:
-73.72%
1日の値動き範囲:
$1.20
$1.26
1週間の範囲:
$1.13
$1.26
52週間の値動き範囲:
$1.05
$5.17
Adc Therapeutics Sa Stock (ADCT) Company Profile
ADCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.23 | 120.01M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 開始されました | Guggenheim | Buy |
| 2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 開始されました | CapitalOne | Overweight |
| 2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-08-17 | 再開されました | Jefferies | Buy |
| 2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-09 | 開始されました | BofA/Merrill | Buy |
| 2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com
Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter
Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Neuroendocrine tumors Pipeline Analysis and Clinical Trials - openPR.com
SEC Form PRE 14A filed by ADC Therapeutics SA - Quantisnow
HC Wainwright Lifts Earnings Estimates for ADC Therapeutics - MarketBeat
ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - MarketScreener
Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX
ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat
Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World
Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology
Guggenheim Has Lowered Expectations for ADC Therapeutics (NYSE:ADCT) Stock Price - MarketBeat
ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - Defense World
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK
ADCT stock touches 52-week low at $1.36 amid sharp annual decline - Investing.com
Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital maintains Outperform on ADC Therapeutics stock By Investing.com - Investing.com UK
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates - MSN
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - StreetInsider.com
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market - MSN
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics Q4 Net Income USD -30.727 Million - MarketScreener
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Finan - GuruFocus
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue By Investing.com - Investing.com South Africa
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue - Investing.com
ADC THERAPEUTICS SA -REDH Earnings Results: $ADCT Reports Quarterly Earnings - Nasdaq
A Preview Of ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation a - GuruFocus
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - StreetInsider
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 – Company Announcement - Financial Times
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):